BeOne Medicines AG (ONC)
NASDAQ: ONC · Real-Time Price · USD
279.93
+0.93 (0.33%)
At close: Jun 4, 2026, 4:00 PM EDT
279.00
-0.93 (-0.33%)
After-hours: Jun 4, 2026, 7:20 PM EDT

BeOne Medicines AG Stock Forecast

Stock Price Forecast

According to 28 analysts polled by S&P Global, BeOne Medicines AG stock has a consensus rating of "Strong Buy" and an average price target of $411.91. The average 1-year stock price forecast is 47.15% higher than the current stock price, while the lowest is $333 (+18.96%) and the highest is $501.3 (+79.08%).

Price Target: $411.91 (+47.15%)
Analyst Consensus: Strong Buy
TargetLowAverageMedianHigh
Price$333$411.91$410.5$501.3
Change+18.96%+47.15%+46.64%+79.08%

Analyst Ratings

The average analyst rating for BeOne Medicines AG stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

RatingJan '26Feb '26Mar '26Apr '26May '26Jun '26
Strong Buy181818181919
Buy777788
Hold001111
Sell000000
Strong Sell110000
Total262626262828

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Guggenheim
Guggenheim
Buy
Maintains
$420
BuyMaintains$420+50.04%Jun 3, 2026
Wolfe Research
Wolfe Research
Buy
Maintains
$340
BuyMaintains$340+21.46%Jun 3, 2026
Barclays
Barclays
Buy
Maintains
$409
BuyMaintains$409+46.11%Jun 3, 2026
J.P. Morgan
J.P. Morgan
Buy
Maintains
n/a
BuyMaintainsn/an/aJun 2, 2026
TD Cowen
TD Cowen
Buy
Reiterates
$424
BuyReiterates$424+51.47%Jun 2, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
45.30B
from 37.37B
Increased by 21.22%
Revenue Next Year
51.92B
from 45.30B
Increased by 14.62%
EPS This Year
3.36
from 17.28
Decreased by -80.56%
EPS Next Year
5.29
from 3.36
Increased by 57.47%
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
7.47B9.77B17.43B27.81B37.37B45.30B
Revenue Growth
270.56%30.69%78.53%59.51%34.37%21.22%
Gross Profit
6.42B7.79B14.74B23.48B32.70B39.52B
Gross Margin
85.98%79.77%84.55%84.41%87.49%87.23%
Operating Income
-9.14B-12.34B-8.56B-4.15B3.13B5.95B
Net Income
-9.26B-13.82B-6.25B-4.71B2.01B5.31B
EPS
-99.81-134.01-59.92-44.7017.283.36
EPS Growth
------80.56%
Forward PE
----66.95564.60
Free Cash Flow
-7.65B-6.51B-9.03B-2.71B4.98B4.98B
No. Analysts
-----35
Financial currency is CNY.

Revenue Forecast

Revenue202620272028
High47.9B
Avg45.3B
Low43.4B

Revenue Growth

Revenue Growth202620272028
High
28.1%
Avg
21.2%
Low
16.3%

EPS Forecast

EPS202620272028
High3.78
Avg3.36
Low2.94

EPS Growth

EPS Growth202620272028
High
-78.1%
Avg
-80.6%
Low
-83.0%
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by TipRanks. Financial forecast data provided by S&P Global Market Intelligence. The data is sourced from Wall Street analysts. Data sources.